Passage Bio, Inc.

PASG Healthcare Biotechnology

In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

3.48 0.12 −3.33%
Market cap
$11.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

2.51 2.07 1.73 1.22
Net Debt/EBITDA
6.23 3.39 4.11 2.93
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.63 0.50 1.72 1.17
Capex/Depreciation
0.00 0.00 0.16 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(1.53) (2.04) (4.04) (2.86)
Cash per Share
16.60 14.59 10.40 7.53
Shareholders Equity per Share
9.79 5.91 3.67 1.39
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
9.79 5.91 3.67 1.39
Free Cash Flow
(4.85) (6.48) (12.97) (9.18)
Working Capital
33.49 24.68 14.64 4.46
Capital Expenditures
0.00 0.00 0.02 0.00
Net Current Asset Value
12.69 4.24 10.03 4.46
Other line items
Quick Ratio
2.37 2.01 1.66 1.17
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(1.53) (2.04) (4.05) (2.86)
Capex per Share
0.00 0.00 0.01 0.00
Average Payables
1.22 0.93 1.38 1.65
Average Assets
92.96 82.35 61.23 52.19
Average Common Equity
51.92 40.01 29.23 21.36
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates